Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06434818 · ClinicalTrials.gov registry record · Phase 2

Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders

A Phase 2 study of Opioid Use Disorder and Alcohol Use Disorder, sponsored by Evon Medics.

Recruiting
Registry status
Phase 2
Development phase
300
Enrollment target
3
Study locations

NCT06434818: Recruiting Phase 2 study of Opioid Use Disorder and Alcohol Use Disorder, sponsored by Evon Medics.

NCT06434818 is a Phase 2 study of Opioid Use Disorder and Alcohol Use Disorder that is actively recruiting participants, run by Evon Medics. The registered enrollment target is 300 participants, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06434818, a Phase 2 study of Opioid Use Disorder and Alcohol Use Disorder, is actively recruiting participants, sponsored by Evon Medics.

RECRUITING
Registry status
Phase 2
Development phase
300 participants
Enrollment target
3
Study locations

Study Summary

The overarching goal of this study phase, Phase II component is to implement Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders (EDITOR) device in substance use disorder (SUD) clinics to demonstrate pilot effectiveness for SUD outcomes compared to treatment as usual (TAU) and Computerized Chemosensory-Based Orbitofrontal Networks Training (CBOT) device as active control. The investigators will conduct a multi-site study of 300 adult patients with opiate use disorder (OUD), stimulant (i.e., cocaine, methamphetamine) and/or alcohol use disorder (AUD) from community and clinics to evaluate whether EDITOR is associated with better patient treatment outcomes (e.g., retention in treatment and abstinence). The pilot study will provide preliminary data needed for design of a Phase III trial, including estimates of effect size. The investigators will also explore development of machine learning/AI algorithms integrating clinical and physiological data into treatment decision guides for providers.

Conditions Studied

Opioid Use Disorder Alcohol Use Disorder Substance Use Disorders Cocaine Use Disorder Methamphetamine-dependence

Interventions

  • COMBINATION_PRODUCT EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance)
  • COMBINATION_PRODUCT CBOT with olfactory stimulants & OFC tasks
  • COMBINATION_PRODUCT CBOT Sham

Study Locations (3)

District of Columbia

  • Clinics of Dr. Edwin Chapman @ MHDG - Washington D.C.
  • Howard University - Washington D.C.

Maryland

  • Maryland Treatment Center - Rockville

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2023-07-07
Est. Completion 2025-06-30
Phase Phase 2
Evon Medics

3 total trials

What NCT06434818 shows while recruiting

NCT06434818 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (94% lower).

The record links to 5 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 3 interventions - of which EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance) is the first listed.

NCT06434818 reports a single indexed study location in District of Columbia, Maryland.

Frequently Asked Questions

What is clinical trial NCT06434818 about?

NCT06434818 is a clinical study titled "Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders". The overarching goal of this study phase, Phase II component is to implement Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders (EDITOR) device in substance use disorder (SUD) clinics to demonstrate pilot effectiveness for SUD outcomes compared to...

What is the current status of trial NCT06434818?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2023-07-07. Estimated completion is 2025-06-30.

What conditions does trial NCT06434818 study?

This clinical trial studies the following conditions: Opioid Use Disorder, Alcohol Use Disorder, Substance Use Disorders, Cocaine Use Disorder, Methamphetamine-dependence.

What interventions are being tested in trial NCT06434818?

The interventions under investigation include: EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance) (COMBINATION_PRODUCT), CBOT with olfactory stimulants & OFC tasks (COMBINATION_PRODUCT), CBOT Sham (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT06434818?

This trial is sponsored by Evon Medics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06434818 being conducted?

This trial has 3 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06434818's enrollment target sits among peer trials

300 57th of 257 higher than 196 of 257 other Opioid Use Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06434818

Source: ClinicalTrials.gov NCT06434818, the US trial registry maintained by the National Library of Medicine. NCT06434818 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.